case_images: PMC7879677_01
case_images: (A) The patient under mycophenolate-mofetil 2 g/day and topical corticosteroids (before therapy with dupilumab and omalizumab), (B) 2 months after addition of omalizumab therapy to his therapy protocol, (C) stable clinical results, 3 months after addition of dupilumab to his therapy protocol.
case_images: fimmu-11-611549-g001.jpg
case_images: PMC7879677_01_fimmu-11-611549-g001.jpg
case_images: f1
case_images: Three months later, the patient remained in complete remission on combination of omalizumab and dupilumab with no clinical or biological side effects and ELISA-BP180 levels remained stable (24.8 U/ml). ( Figures 1 ,  2 ).
case_images: Histopathological image of the lesions, which is compatible with urticarial dermatitis with presence of ulceration and eosinophils.
case_images: fimmu-11-611549-g002.jpg
case_images: PMC7879677_01_fimmu-11-611549-g002.jpg
case_images: f2
case_images: Three months later, the patient remained in complete remission on combination of omalizumab and dupilumab with no clinical or biological side effects and ELISA-BP180 levels remained stable (24.8 U/ml). ( Figures 1 ,  2 ).